# EDGAR Filing Document

**Accession Number:** 0001645666
**File Stem:** 0001140361-26-020555
**Filing Date:** 2026-5
**Character Count:** 9494
**Document Hash:** 2acd573c75c6c6aae64ac444c8e780f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-020555.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001140361-26-020555

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**EFFECTIVENESS DATE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kezar Life Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001645666
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473366145
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-263659
- **FILM NUMBER:** 26963306

**BUSINESS ADDRESS:**
- **STREET 1:** 4000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-822-5600

**MAIL ADDRESS:**
- **STREET 1:** 4000 SHORELINE COURT, SUITE 300
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

#### As filed with the Securities and Exchange Commission on May 11, 2026

#### Registration No. 333-225769

#### Registration No. 333-230520

#### Registration No. 333-237133

#### Registration No. 333-254161

#### Registration No. 333-263659

#### Registration No. 333-271841

#### Registration No. 333-277939

#### Registration No. 333-286084

#### <br>

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-225769

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230520

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237133

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-254161

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-263659

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-271841

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-277939

#### POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-286084

### FORM S-8

#### REGISTRATION STATEMENT

#### UNDER

#### THE SECURITIES ACT OF 1933

------

## KEZAR LIFE SCIENCES, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | |
|:---|:---|
| **Delaware** | **47-3366145** |
| **(State or other jurisdiction of incorporation or organization)** | **(IRS employer identification number)** |

---

#### 4000 Shoreline Court, Suite 300

#### South San Francisco, California 94080

#### (Address of Principal Executive Offices, including Zip Code)

------

#### Kezar Life Sciences, Inc. 2015 Equity Incentive Plan

#### Kezar Life Sciences, Inc. 2018 Equity Incentive Plan

#### Kezar Life Sciences, Inc. 2018 Employee Stock Purchase Plan

#### Kezar Life Sciences, Inc. 2022 Inducement Plan

#### (Full title of the Plans)

#### <br>

#### Michael Hearne

#### Chief Financial Officer

#### Kezar Life Sciences, Inc.

#### 77 Upper Rock Circle, Suite 700

#### Rockville, Maryland 20850
(250) 744-2487

#### (Name, Address and Telephone Number, including Area Code, of Agent for Service)

#### Copies to :

#### Andrew Marmer

#### Jared Fertman

#### Willkie Farr & Gallagher LLP

#### 787 Seventh Avenue

#### New York, NY 10019-6099
(212) 728-8000

#### Bill Roegge

#### Rita Sobral

#### Cooley LLP

#### 55 Hudson Yards

#### New York, NY 10001-2157
(212) 479-6000

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer, "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

#### EXPLANATORY NOTE

#### DEREGISTRATION OF UNSOLD SECURITIES
These Post-Effective Amendments (the "<u>Post-Effective Amendments</u>") filed by Kezar Life Sciences, Inc., a Delaware corporation (the "<u>Registrant</u>"), to deregister all shares of the Registrant's common stock, par value $0.001 per share (the "<u>Shares</u>"), remaining unissued under the following Registration Statements on Form S-8 (each, a "<u>Registration Statement</u>", and collectively, the "<u>Registration Statements</u>") filed by the Registrant with the U.S. Securities and Exchange Commission (the "<u>Commission</u>").

• Registration Statement on Form S-8 (No. 333-225769) pertaining to the registration of (i) 2,102,045 options issuable under the Kezar Life Sciences, Inc. 2015 Equity Incentive Plan (the "2015 Plan") , (ii) 1,845,465 Shares issuable under the Kezar Life Sciences, Inc. 2018 Equity Incentive Plan (the "2018 Plan"), (iii) 52,490 options issuable under the 2018 Plan and (iv) 200,000 Shares issuable under the Kezar Life Sciences, Inc. 2018 Employee Stock Purchase Plan
 (the " <u>ESPP</u> ").

• Registration Statement on Form S-8 (No. 333-230520) pertaining to the registration of (i) 955,721 Shares issuable under the 2018 Plan and (ii) 191,144 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-237133) pertaining to the registration of (i) 960,403 Shares issuable under the 2018 Plan and (ii) 192,080 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-254161) pertaining to the registration of (i) 2,317,987 Shares issuable under the 2018 Plan and (ii) 375,000 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-263659) pertaining to the registration of (i) 2,812,987 Shares issuable under the 2018 Plan and (ii) 375,000 Shares issuable under the ESPP.

• Registration Statement on Form S-8 (No. 333-271841) pertaining to the registration of (i) 3,424,671 Shares issuable under the 2018 Plan, (ii) 1,995,000 Shares issuable under the Kezar Life
 Sciences, Inc. 2022 Inducement Plan (the " <u>2022 Plan</u> ") and (iii) 1,005,000 options under the 2022 Plan.

• Registration Statement on Form S-8 (No. 333-277939) pertaining to the registration of 3,638,953 Shares issuable under the 2018 Plan.

• Registration Statement on Form S-8 (No. 333-286084) pertaining to the registration of 365,181 Shares issuable under the 2018 Plan.

The Registrant is filing these Post-Effective Amendments to withdraw and remove any unissued and unsold securities issuable by the Registrant pursuant to the above-referenced Registration Statements.

On March 30, 2026, the Registrant entered into an Agreement and Plan of Merger (the "<u>Merger Agreement</u>") with Aurinia Pharma U.S., Inc., a Delaware corporation ("<u>Parent</u>"), and Aurinia Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("<u>Merger Sub</u>"). Pursuant to the Merger Agreement, on May 11, 2026, Merger Sub was merged with and into the Registrant with the Registrant surviving as a wholly owned subsidiary of Parent (the "<u>Merger</u>"). In the Merger, each share of common stock, par value $0.001 per share, of the Company (the "<u>Shares</u>") (other than (i) Shares owned or held in the Company's treasury immediately prior to the Effective Time, (ii) Shares owned directly or indirectly by Parent or Merger Sub immediately prior to the Effective Time and (iii) Shares held by any stockholder of the Registrant who properly exercised appraisal rights under Delaware law) was converted into the right to receive (i) $6.955 per Share in cash and (ii) one non-transferable contractual contingent value right for each Share.

As a result of the Merger, the Registrant has terminated all offerings of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all such securities registered under the Registration Statements that remain unsold as of the date hereof and terminates the effectiveness of the Registration Statements.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing these Post-Effective Amendments to the Registration Statements and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on May 11, 2026. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

---

| |
|:---|
| **KEZAR LIFE SCIENCES, INC.** |
|  /s/ Michael Hearne |
|  Name: Michael Hearne |
|  Title: Chief Financial Officer |

---

------